ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO249

Raising Serum Uric Acid With a Uricase Inhibitor Worsens Polycystic Kidney Disease in Rat and Mouse Models

Session Information

Category: Genetic Diseases of the Kidneys

  • 1101 Genetic Diseases of the Kidneys: Cystic


  • Atwood, Daniel, Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Istanbul, Turkey
  • Oto, Ozgur Akin, Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Istanbul, Turkey
  • Chaudhary, Anjana, Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Istanbul, Turkey
  • Edelstein, Charles L., Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Istanbul, Turkey

Humans are predisposed to gout because they lack uricase that converts uric acid to allantoin. In rodents uricase converts uric acid to allantoin and uricase inhibition raises serum uric acid. The aim of the study was to determine whether raising serum uric acid with the uricase inhibitor oxonic acid (OXO) was associated with worse PKD.


Orthologous models of human PKD were used. PCK rats, a Pkhd1 gene model of ARPKD and Pkd1RC/RC (RC) mice, a hypomorphic Pkd1 gene model. OXO 750 mg/kg by mouth in rats from day 21-84 of age and 300 mg/kg IP in mice from day 50-120 of age was used. Uric acid and allantoin were measured by LC/MS-MS. Creatinine was measured by HPLC. Males and females were analyzed together. 12 pro-inflammatory cytokines were measured by MesoScale technology.


On IHC staining, xanthine oxidase (that converts xanthine to uric acid) was strongly present in normal tubules in PCK rats. In pharmacokinetic studies in rats, there was a 5 -fold increase in serum uric acid 2 hrs after OXO 100 mg/kg (IP or orally), that returned to normal in 8 hrs. OXO resulted in decreased allantoin in PCK rats. In PCK rats and RC mice, OXO resulted in a significant increase in serum uric acid, 2 kidney/body weight ratio (2K/BW) (%), cyst index (% of kidney that was cystic on cross sections) and creatinine (Table). OXO resulted in an increase in pro-inflammatory cytokines in the serum in RC mice.


Increasing serum uric acid by inhibiting uricase with OXO results in an increase in kidney weight, cyst index, creatinine in PCK rats and RC mice Potential mechanisms of increased cyst growth that will be investigated include crystal deposition causing tubular dilatation, increased reactive oxygen radicals and pro-inflammatory cytokines/chemokines causing tubular cell proliferation and endothelial injury.

Uric acid (µM)2227<0.0520.130.70.17
Allantoin (µM)4.33.1<0.05N/AN/AN/A
2K/BW (%)0.860.96<<0.05
Cyst index (%)814<0.05610<0.05
Creatinine (mg/dL)<0.05
IFN-γ/IL-5/TNF-α (mg/dL)N/AN/AN/A0.1/1.6/2.80.4/5.6/4.10.06


  • Veterans Affairs Support –